Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
US FDA unveils new pathway to approve personalized therapies - 2The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- 3Bahrain cracks down on dissent as war grinds on
- 4Figure out How to Augment the Advantages of a Web-based Degree
- 5Energy agency chief warns of 'black April' for oil supplies
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- Find Your Ideal Tea: Six Particular Assortments
- Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- Oil magnate’s Venezuela detainment spooks industry
- Can a mammogram help identify heart disease?
- Ukraine to get up to 100 French-made Rafale fighter jets
- Fascinating Fishing Objections From Around The World
- A definitive Manual for the 5 Off-road Bicycles Available
- Vote in favor of the subject that you see as generally captivating and intelligent!
